HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACA Repeal Wave Could Add Supplements To Pre-Tax Savings Purchases

This article was originally published in The Rose Sheet

Executive Summary

Sen. Orrin Hatch and Rep. Erik Paulsen author the Health Savings Act of 2017 proposing a broad swath of changes to replace the ACA, including allowing dietary supplements as deductible medical expenses under pre-tax savings accounts and eliminating the Rx requirement to buy OTC drugs with the accounts.

You may also be interested in...



It’s Complicated: Health Care Act Simplifies Buying OTCs With Pre-Tax Accounts

CHPA gives tempered support for White House-backed legislation to replace the Affordable Care Act because it would eliminate requirement that consumers can only use pre-tax savings accounts for OTCs if they have a prescription.

It’s Complicated: Health Care Act Simplifies Buying OTCs With Pre-Tax Accounts

CHPA gives tempered support for White House-backed legislation to replace the Affordable Care Act because it would eliminate requirement that consumers can only use pre-tax savings accounts for OTCs if they have a prescription.

OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House

With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel